Current Developments in the Preclinical and Clinical use of Natural Killer T cells.
Christina KratzmeierSasha SinghEmmanuel B AsieduTonya J WebbPublished in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2022)
Natural killer T (NKT) cells play a pivotal role as a bridge between the innate and the adaptive immune response and are instrumental in the regulation of homeostasis. In this review, we discuss the potential for NKT cells to serve as biodrugs in viral infections and in cancer. NKT cells are being investigated for their use as a prognostic biomarker, an immune adjuvant, and as a form of cellular therapy. Historically, the clinical utility of NKT cells was hampered by their low frequency in the blood, discrepancies in nomenclature, and challenges with ex vivo expansion. However, recent advances in the field have permitted the development of several NKT cell-based preclinical and clinical strategies. These new developments pave the way for the successful implementation of NKT cell-based approaches for the treatment of human disease.
Keyphrases
- induced apoptosis
- immune response
- cell cycle arrest
- cell therapy
- endoplasmic reticulum stress
- healthcare
- primary care
- oxidative stress
- single cell
- signaling pathway
- risk assessment
- young adults
- dendritic cells
- mesenchymal stem cells
- high resolution
- combination therapy
- induced pluripotent stem cells
- replacement therapy